Femasys is trading 5.7% lower at $1.66, with no clear company-specific catalyst; broader market and biotech pressure may be contributing. - On October 14, Femasys said it had doubled actively enrolling sites in its FemBloc pivotal trial to twelve; the announcement did not report a share-price reaction. - U.S. stocks fell after hotter-than-expected September inflation heightened rate-hike concerns, while biotech stocks were also under pressure.